AI Stock Monitor
MRK - Merck
Merck is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Pharmaceuticals · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NYSE · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
75
/100
Price History
MRK chart
AI-Assisted Chart Analysis
Merck technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Constructive uptrend: the latest level is above the 50-period average and the 50-period average is above the 200-period average.
RSI is 66, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 120.78. A break below 111.38 invalidates the near-term support setup.
The first resistance/watch zone is 131.82. A confirmed break above 131.82 supports continuation.
Annualized realized volatility is +27.7%. Maximum lookback drawdown is -11.9%, from a high-water mark of 123.93 to 109.18.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported MRK at 130.70 USD; the latest daily move rose +1.65%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified +1.65% daily move is current market context for Merck.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The signal is Bullish, supported by a strong Q2 earnings performance and an upward revision to full-year guidance.
- Evidence: The company's ability to beat estimates while simultaneously raising its outlook demonstrates robust operational execution in its core oncology and vaccine segments.
- Uncertainty: While the reliance on Keytruda is well-documented, the progress in the HIV pipeline and other regulatory milestones provides a necessary narrative for long-term growth beyond the current blockbuster cycle.
- Watch: Uncertainty remains regarding the long-term impact of drug pricing legislation and the competitive landscape in oncology, which could temper valuation expansion.
Key Risks
- Concentration risk remains high, as the company's valuation is heavily tied to the continued commercial success and label expansion of Keytruda.
- Regulatory and legislative pressures on drug pricing could compress margins or limit the pricing power of key blockbuster assets.
- Clinical trial failures or regulatory setbacks in the pipeline, particularly for the HIV or oncology assets, would directly threaten long-term growth projections.
Upcoming Catalysts
- Future FDA decisions on pipeline assets will be critical for validating the company's R&D strategy and long-term revenue growth.
- Quarterly earnings calls will serve as the primary venue for management to update guidance and provide color on the competitive landscape.
- Updates on the commercial rollout of new drug launches will be key to demonstrating the company's ability to diversify its revenue base.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceAnalyst Opinion1MRK - Merck KGaA News - Morningstar · Published 2026-08-10 09:05:53Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceAnalyst OpinionMerck KGaA (MKKGY) Q2 2026 Earnings Call Transcript - Seeking Alpha · Published 2026-08-10 09:05:53Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceAnalyst OpinionMerck KGaA (MKKGY) Q2 2026 Earnings Call Transcript - Seeking Alpha · Published 2026-08-10 09:05:53Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedMRK Stock Price | Merck & Co. Inc. Stock Quote (U.S.: NYSE) - marketwatch.com · Published 2026-08-10 09:05:53Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedThe Two Divergent Paths Priced Into Eli Lilly Stock · Published 2026-08-10 09:05:53Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.